INDOCO Intraday Analysis...

INDOCO Share Price

Open 203.50 Change Price %
High 205.00 1 Day 1.70 0.84
Low 200.80 1 Week 5.05 2.54
Close 204.20 1 Month 9.35 4.80
Volume 14832 1 Year -123.80 -37.74
52 Week High 352.40
52 Week Low 178.10
INDOCO Important Levels
Resistance 2 208.09
Resistance 1 206.49
Pivot 203.33
Support 1 201.91
Support 2 200.31
NSE INDIA Most Active Stocks
JPASSOCIAT 18.55 5.10%
SOUTHBANK 31.45 8.26%
UNITECH 7.35 5.00%
IDEA 80.15 -3.67%
RCOM 19.75 -1.74%
ADANIPOWER 32.35 2.05%
DIVISLAB 942.80 9.22%
SUZLON 16.75 0.00%
HUDCO 89.45 1.36%
BOMDYEING 202.80 4.89%
More..
NSE INDIA Top Gainers Stocks
KSERASERA 0.15 50.00%
PANORAMUNI 9.60 20.00%
VIVIMEDLAB 138.20 19.97%
INDOTECH 256.60 19.24%
NAKODA 0.35 16.67%
ITDC 580.50 16.65%
HIRECT 143.25 15.57%
GSCLCEMENT 38.40 14.12%
DAMODARIND 109.80 13.96%
WALCHANNAG 231.50 13.96%
More..
NSE INDIA Top Losers Stocks
PRAKASHCON 4.55 -7.14%
PREMIERPOL 36.65 -6.51%
DQE 18.35 -6.38%
INTENTECH 87.35 -6.33%
PRATIBHA 10.00 -6.10%
SWANENERGY 148.25 -5.81%
TAKE 158.95 -5.72%
COMPUSOFT 14.10 -5.69%
SYNCOM 5.05 -5.61%
LITL 0.85 -5.56%
More..

Indoco Remedies Limited (NSE: INDOCO)

INDOCO Technical Analysis 2
As on 20th Sep 2017 INDOCO Share Price closed @ 204.20 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 237.85 & Buy for SHORT-TERM with Stoploss of 198.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
INDOCO Target for September
1st Target up-side 209.73
2nd Target up-side 221
3rd Target up-side 232.27
1st Target down-side 177.57
2nd Target down-side 166.3
3rd Target down-side 155.03
INDOCO Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 62.79 Sideways
MFI (14) MFI is 55.39 Sideways
CCI (20) CCI is Above 100 Over Bought
WILLIAM %R (14) William %R is Above -20 Over Bought
ADX (14) ADX is 19.33 Range Bound
PSAR Stoploss For Long Buy 184.81
10 Day Avg Volume Traded -52.37 % Less then 10 Day Average Volume
INDOCO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.indoco.com
INDOCO Address
INDOCO
Indoco House
166 CST Road
Mumbai, 400098
India
Phone: 91 22 2654 1851
Fax: 91 22 2652 0787
INDOCO Latest News
Indoco Remedies Q3 Net up 53 pc at Rs 21.6 crore   Economic Times   - 30th Jan 15
Indoco Remedies Ltd to consider Q3 results on Jan 30, 2015   Equity Bulls   - 17th Jan 15
Indoco Remedies Q2 net profit grows by 40 pc   Business Standard   - 21st Oct 14
Indoco Remedies Q1 profit up 118 pc; to file 10 ANDAs in FY15   Business Standard   - 30th Jul 14
Indoco Remedies' facilities in Goa receive FDA approval   VC Circle   - 22nd Jul 14
Indoco Remedies shares fall over US FDA 483   Business Standard   - 17th Jan 14
Indoco Remedies optimizing opportunities, says Nirmal Bang   Moneycontrol.com   - 31st Aug 13
Baring Buys And Reliance Capital Sells Shares Of Indoco Remedies   DealCurry   - 03rd Jul 13
Indoco Remedies launches new division, Indoco CND   pharmabiz.com   - 05th Apr 12
Indoco Remedies sees turnover doubling in two years   Daily News & Analysis   - 19th Aug 11
Interactive Technical Analysis Chart Indoco Remedies Limited ( INDOCO NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Indoco Remedies Limited
INDOCO Business Profile
Based in Mumbai, Indoco Remedies was formed in Aug. 23, 1947. Indoco Remedies (INDOCO) makes formulations. The company also has a presence in contract manufacturing and research. It also trades some active pharma ingredients (APIs) manufactured by a group company. It has presence in the therapeutic segments including anti-infective, anti-cold preparation, opthalmic, anti-spasmodic, stomatology, anti-inflammatory and anti-fungal. The company`s shareholders are SPA Pharmaceuticals and Shanteri Investments. The company recently launched a new super specialty division with focus on diabetic and cardio-vascular segments. It has formed a 100% subsidiary, Indoco Holdings Netherlands BV, which would invest in Indoco UK and Indoco SA Pty a JV in South Africa. Indoco`s other subsidiary is Indoco Healthcare. In 2004-05, Indoco launched Methycal, a unique calcium supplement. It also acquired a brand Karvol Plus in the segment of decongestive inhalant from M/s Solvay Pharma (I) . Indoco availed of ECB loan of USD 2.50 million for financing the expansion of tablet facility of plant I at Verna. INDOCO exports branded formulations to several Asian and African countries. The current market capitalization stands at Rs 947.31 crore. Indoco Remedies has reported a standalone sales turnover of Rs 202.30 crore and a net profit of Rs 16.04 crore for the quarter ended September 2013. Other income for the quarter was Rs 0.42 crore. The company management includes Suresh G Kare - Chairman, Aditi Panandikar - Managing Director, Sundeep V Bambolkar - Joint Managing Director, D M Gavaskar - Director, Rajiv P Kakodkar - Director, Sharad P Upasani - Director, Anil M Naik - Director. The Registered office is at Indoco House, 166 CST Road, Kalina, Mumbai, Maharashtra - 400098.